News Focus

Can Data Banks Tally Profits?

Science  16 Feb 2001:
Vol. 291, Issue 5507, pp. 1203
DOI: 10.1126/science.291.5507.1203

You are currently viewing the summary.

View Full Text

Summary

Celera's high-powered sequencing has achieved impressive results, but it hasn't yet translated into a healthy bottom line. Like most biotech start-ups, the nearly-3-year-old company has yet to turn a profit. And, although the company's stock rocketed after going public in May 1999, its price tanked over the past year, along with that of other biotechs, from a high of $275 a share to about $50 today.

Related Content